IMUNON (IMNN) announced new data from its first Phase 1 proof-of-concept clinical trial of IMNN-101, an investigational DNA plasmid vaccine based on the Company’s proprietary PlaCCine technology platform, for protection against COVID-19. Results in 24 healthy volunteers demonstrated IMNN-101’s durability of protection at six months after a single dose targeting the SARS-CoV-2 Omicron XBB1.5 spike antigen variant. IMNN-101 induced up to a 3-fold median increase in the serum neutralizing antibody titers from baseline at six months, with initial evidence of a stronger immune response in two higher dose cohorts compared to a lower dose cohort. The highest observed increase among the participating volunteers was 8-fold from baseline. IMNN-101 continues to be safe and well tolerated, with no serious adverse effects reported.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- Imunon price target lowered to $17 from $29 at D. Boral Capital
- Imunon Announces Warrant Exchange for Equity Securities
- Positive Outlook on Imunon Driven by Advancements in OVATION 3 Study and Strategic Focus on HRD+ Patients
- IMUNON, Inc. Reports Q1 2025 Financial Results and Clinical Progress
- Imunon, Inc. Earnings Call: Clinical Progress Amid Financial Challenges